Amgen’s Q2 Revenue Rises 20% Despite Higher Expenses
Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
- Latest
- Trending
Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
Trinity Biotech plc gets a "buy" rating from StockNews.com analysts, spotlighting potential for investors with a focus on its diagnostic ...
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
NHS chief urges tighter cryptocurrency controls, citing rise in gambling issues potentially escalating NHS service demand. — The Telegraph, June ...
Trinity Biotech (NASDAQ:TRIB) stock plummets 19.7%, with shares opening at $2.78. Despite a 52-week high of $5.50, the market cap ...
Pfizer's interest in the weight loss market is uncertain due to its significant debt of over $70 billion and recent ...
The FDA will now allow yogurt makers to claim that their products may prevent Type 2 diabetes, based on limited ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.